Mirtazapin Sandoz (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases the release of norepinephrine and serotonin. It also antagonizes certain serotonin (5‑HT2, 5‑HT3) and histamine (H1) receptors, contributing to its antidepressant and sedative effects.

The appropriate dose of Mirtazapin Sandoz is determined by the prescribing clinician based on the individual patient's condition, response, and tolerability. Dosage adjustments are made according to clinical judgment and patient needs.

Safety of mirtazapine in pregnancy has not been fully established, and it is generally prescribed only when the potential benefit outweighs the risk. Its excretion in breast milk is unknown, so caution is advised and alternative treatments may be considered.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirtazapin Sandoz belongs to the NaSSA class, which differs from SSRIs and SNRIs by its dual antagonism of α2‑adrenergic and specific serotonin receptors. This mechanism often results in pronounced sedative and appetite‑stimulating effects, making it useful for patients with insomnia or weight loss, whereas other antidepressants may lack these properties.

Mirtazapin Sandoz should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the tablets from moisture, excessive heat and direct sunlight to maintain product stability.

Mirtazapin Sandoz is taken orally, usually once daily in the evening, as directed by the prescriber. The tablets should be swallowed whole with water and not crushed or chewed unless otherwise instructed.

Serious risks include the potential for agranulocytosis, severe neutropenia, Stevens‑Johnson syndrome, and increased suicidal thoughts, especially when initiating therapy or adjusting dose. Patients should be monitored for signs of infection, skin reactions, or worsening mood.

Mirtazapin Sandoz is contraindicated in patients who have taken a monoamine oxidase inhibitor within the past 14 days. Caution is also advised for individuals with known hypersensitivity to mirtazapine or any of its excipients, and for those with severe hepatic impairment.